National Institute of Allergy and Infectious Diseases (NIAID)
Phase 3
2000-06-01
The purpose of this study is to determine if azithromycin, a drug approved for treatment of
other infections, is as effective for syphilis (a sexually transmitted disease) as the
standard treatment. Approximately 600 healthy adults, who are HIV-negative, ages 18 to 55
years of age, with primary, secondary or early latent syphilis, will participate in this
research study. Volunteers will be enrolled in 5 U.S. cities and in Madagascar. Participants
will be chosen randomly (by chance) to receive 1 of 2 study drugs: benzathine penicillin
given (2 shots in the buttocks) or 4 tablets of azithromycin. Subjects who report a history
of a penicillin allergy will be given either 2.0 g of oral azithromycin or 100 mg doxycycline
taken orally, twice a day for 14 days. Over 2 years, 10 visits will be required. Procedures
will include blood samples, physical exams, and swabs of sores.
Bicillin L-A vs Placebo for the Treatment of Chronic, Plaque-Type Psoriasis Unresponsive to Topical Medications
Terminated
University of Tennessee
Phase 2
2007-01-01
The purpose of this study is to determine the efficacy for Bicillin L-A, administered
intramuscularly in a dose of 2.4 million units every three (3) weeks, for the treatment of
chronic, plaque-type psoriasis unresponsive to topical medications or when other systemic
therapies are contraindicated.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
